Press release
Ibutilide Impurity Standards - Ensuring Accuracy in Antiarrhythmic Drug Analysis
Overview of IbutilideIbutilide is a class III antiarrhythmic agent widely prescribed for the acute conversion of atrial fibrillation and atrial flutter. Its mechanism of action prolongs cardiac action potential and refractoriness, helping restore normal sinus rhythm. Given its therapeutic importance, regulatory authorities require rigorous quality control - and that's where Ibutilide impurity standards come into play.
https://aquigenbio.com/product/ibutilide-fumarate/
At Aquigen Bio, we provide high-purity impurity reference standards for Ibutilide to support pharmaceutical R&D, quality control, and regulatory submissions.
Our Ibutilide Impurity Standards Portfolio
We offer a comprehensive range of Ibutilide-related compounds, including:
Ibutilide Fumarate - The pharmacopeial API standard
Ibutilide Impurity 1 - A known degradation product critical for stability profiling
Ibutilide USP Related Compound A - Defined in USP monographs for compliance testing
Ibutilide USP Related Compound B - Another USP-recognized impurity standard
All our standards are synthesized with stringent purity controls, fully characterized, and supplied with detailed Certificates of Analysis (CoA) for traceability.
https://aquigenbio.com/product/ibutilide-impurity-1/
Importance of Ibutilide Impurity Standards
Pharmaceutical laboratories require impurity standards for:
Analytical Method Development & Validation - Ensuring accurate detection and quantification of Ibutilide and its impurities.
Stability Studies - Monitoring the formation of Ibutilide Impurity 1 and other degradation products under stress conditions.
Regulatory Compliance - Meeting USP, EP, and ICH guidelines for impurity profiling.
Quality Assurance - Safeguarding drug safety, efficacy, and shelf-life through robust testing.
https://aquigenbio.com/product/ibutilide-usp-related-compound-a/
Applications in the Pharmaceutical Industry
Application
Benefit
Quality Control Testing
Validate assay performance with known reference materials
Stability & Degradation Studies
Identify and quantify Ibutilide-related impurities over time
Regulatory Submissions (ANDA/DMF)
Support dossier compliance with USP/EP impurity limits
Research & Development
Enhance formulation studies and impurity identification
Aquigen Bio Sciences
281/1, Plot No 41,
Hinjawadi - Pirangut Rd,
Kasar Amboli, Pirangut,
Pune, Maharashtra 412108
Visit: www.aquigenbio.com
Aquigen Bio is a leading provider of certified reference standards, impurity profiling compounds, and research chemicals to pharma, biotech, and academic institutions worldwide. With a dedication to excellence and a focus on regulatory readiness, Aquigen empowers scientists to innovate with confidence.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ibutilide Impurity Standards - Ensuring Accuracy in Antiarrhythmic Drug Analysis here
News-ID: 4145282 • Views: …
More Releases from Capital Market Solutions

Powering Precision in Regulatory Compliance: How the Cloud Transforms RSMS, CAIS …
In a world where regulatory demands evolve relentlessly, financial institutions must move beyond legacy systems. Embracing cloud-based RegTech-especially for Regulatory Surveillance and Management System (RSMS), Customer Account Information System (CAIS), and Consolidated Audit Trail (CAT) Compliance-is no longer optional, it's foundational.
1. Reinventing Oversight with RSMS in the Cloud
https://capmarketsolutions.com/cat/
A cloud-native Regulatory Surveillance and Management System (RSMS) empowers compliance teams with real-time, unified monitoring across CAT and CAIS channels. Firms can:
Automate cross-system…

Capital Market Solutions Empowers Financial Firms with Scalable, Automated FINRA …
As the financial regulatory landscape accelerates into 2025, Capital Market Solutions (CMS) announces its powerful Regulatory Surveillance and Management System (RSMS)-designed to help financial firms adapt swiftly and confidently to evolving FINRA mandates around CAT and CAIS reporting, exception management, and adherence to Written Supervisory Procedures (WSPs).
Compliance Challenges Demand Smarter Solutions
Financial institutions navigating 2024's escalating regulatory demands are finding that manual workflows and legacy systems are no longer up…

Capital Market Solutions Highlights RSMS Impact on CAT and CAIS Compliance Amid …
As the financial sector reaches the halfway point of a turbulent 2025, Capital Market Solutions (CMS) is drawing attention to the growing need for smarter, faster, and more resilient compliance systems. In its latest thought leadership piece-"Halfway Through 2025 - An RSMS Perspective on Regulatory Compliance"-CMS unpacks the shifting regulatory landscape and the essential role its Regulatory Surveillance and Management System (RSMS) is playing in helping broker-dealers stay audit-ready and…

FINRA CAT Compliance in 2025: A Game-Changer for Regulatory Transparency and Tra …
In the ever-evolving landscape of financial regulation, one initiative has transformed the way U.S. capital markets are monitored and governed: the Consolidated Audit Trail (CAT). Spearheaded by the Securities and Exchange Commission (SEC) and enforced by FINRA, CAT is designed to centralize, standardize, and modernize the audit trail for all U.S. equity and options markets.
CAT is not just another reporting mandate-it's a systemic overhaul of how regulatory bodies gather, analyze,…
More Releases for Ibutilide
Potassium Channel Blocker Drugs (Class III) Market Size, Clinical Trials, Produc …
Potassium Channel Blocker Drugs (Class III) Market Size is estimated to be $456 million in 2024 and is expected to grow at an average yearly rate of around 5% during the timeframe (2025-2032).
What is Potassium Channel Blocker Drugs (Class III) and what are the growth drivers of Potassium Channel Blocker Drugs (Class III) Market?
Potassium channel blocker drugs, categorized under Class III antiarrhythmic agents, are pharmaceutical compounds used to…
Ibutilide Fumarate Market Industry Analysis by Size, Share, Growth, Sourcing Str …
" As of 2024, the global ibutilide fumarate market is valued at approximately $220 million, driven by the increasing prevalence of atrial fibrillation and flutter among aging populations. The market is anticipated to grow significantly, with a projected value of $360 million by 2034, reflecting robust demand for innovative treatments in cardiac care."
Exactitude Consultancy., Ltd. released a research report titled "Ibutilide Fumarate Market". This report covers the global Ibutilide Fumarate…
Natural Astaxanthin Nutritional Health Products Market Key Growth Drivers, Compe …
The Global Natural Astaxanthin Nutritional Health Products Market is set for substantial growth, driven by the rising consumer demand for natural antioxidants with skin, eye, and cardiovascular health benefits.
Natural astaxanthin, primarily derived from Haematococcus pluvialis algae, is known for its potent antioxidant properties, making it popular in skincare, sports nutrition, and dietary supplements.
The Natural Astaxanthin Nutritional Health Products Market was valued at $4.6 billion in 2023 and is projected to…
Halofuginone Market: Dynamics and Future Industry Growth by 2032: Exclusive Rese …
The Halofuginone market was valued at USD 408.25 billion in 2023. It is projected to expand from USD 426.95 billion in 2024 to USD 611.1 billion by 2032, reflecting a compound annual growth rate (CAGR) of approximately 4.58% over the forecast period from 2024 to 2032.
The Global Halofuginone Market Research Report provides a comprehensive analysis of the market segmented by various factors. It examines different dosage forms, including oral and…
Intravenous Immunoglobulin(IVIg) Therapy Market Size, Share and Forecast By Key …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Intravenous Immunoglobulin(IVIg) Therapy market is anticipated to grow at a compound annual growth rate (CAGR) of 9.03% between 2024 and 2031. The market is expected to grow to USD 8.1 Billion by 2024. The valuation is expected to reach USD 14.82 Billion by 2031.
The growing incidence of immunodeficiency disorders and autoimmune diseases is propelling the market for intravenous immunoglobulin (IVIg) therapy.…
Autonomous Robotic Vacuum Cleaner Market Size, Share and Forecast By Key Players …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Autonomous Robotic Vacuum Cleaner market is anticipated to grow at a compound annual growth rate (CAGR) of 16.53% between 2024 and 2031. The market is expected to grow to USD 2.1 Billion by 2024. The valuation is expected to reach USD 6.13 Billion by 2031.
The market for autonomous robotic vacuum cleaners is expanding significantly as a result of rising customer demand…